Bioavailability of diclofenac sodium after pretreatment with diosmin in healthy volunteers

Drug Metabolism and Drug Interactions

Volumn 22, Issue 2-3, 2007, Pages 165-174

  Rajnarayana, K ^a   Venkatesham, A ^a   Krishna, Devarakonda R ^a  

^a KAKATIYA UNIVERSITY   (India)

Author keywords

Bioavailability; CYP2C9; Diclofenac sodium; Diosmin

Indexed keywords

CYTOCHROME P450 2C9; DICLOFENAC; DIOSMIN; UNCLASSIFIED DRUG; VENEX;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OXIDATION;

EID: 34547699154     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2007.22.2-3.165     Document Type: Article

References (14)

1. Ciolinbo HP, Wang TT, Yeh GC. Diosmin and diosmetin are agonists of the aryl hydrocarbon receptor that differentially affect cytochrome P4501A1 activity. Cancer Res 1998; 8: 2754-2760.
2. Cova D, Angelis DL, Giavarini F, Palladini G, Perego R. Pharmacokinetics and metabolism of oral diosmin in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1992; 30: 29-33.
3. Perego R, Beccaglia P, Angelini M, Villa P, Cova D. Pharmacokinetic studies of diosmin and diosmetin in perfused rat liver. Xenobiotica 1993; 23: 1345-1352.
4. Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet 1997; 33: 184-213.
5. Leemann T, Transon C, Bonnabry P, Dayer P. A major role for cytochromeP450TB (CYP2C subfamily) in the actions of non steroidal anti-inflammatory drugs. Drugs Exp Clin Res 1993; 19: 189-195.
6. Bort R, Mace K, Boobis A, Games-Lechon MJ, Pfeifer A, Castell J. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 1999; 8: 787-796.
7. Tang W, Stearing RA, Wang RW, Chiu SH, Baillie TA. Role of human hepatic cytochrome P450 2C9 and 3A4 in the metabolic activation of diclofenac. Chem Res Toxicol 1999; 12: 192-199.
8. Shen S, Marchick MR, Davis MR, Doss GA, Pohl LR. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxy diclofenac. Chem Res Toxicol 1999; 12: 214-222.
9. Tang W, Stearns RA, Bandiera SM, Zhang Y, Raab C, Braun MP. Studies on cytochrome P450-mediated bioactivation of diclofenac in rats and human hepatocytes: identification of glutathione conjugated metabolites. Drug Metab Dispos 1999; 27: 365-372.
10. Krishna DR, Suryakumar J. High performance liquid chromatographic determination of diclofenac sodium in human plasma. Indian J Pharm Sci 1991; 53: 212-214.
11. Krishna DR, Ramkin. A computer program for model independent pharmacokinetic analysis (unpublished).
12. Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450 2C subfamily. Biochemistry 1991; 30: 3247-3255.
13. Bear WL, Teel RW. Effect of citrus phytochemicals on liver and lung cytochrome P450 activity and on the in vitro metabolism of the tobacco specific nitrosamine NNK. Anticancer Res 2000; 20: 3323-3329.
14. Villa P, Cova D, De FL. Protective effect of diosmin on in vitro cell membrane damage and oxidative stress in cultured rat hepatocytes. Toxicology 1992; 73: 179-189.